bionomics-rgb-1024px.png
Bionomics to Present at the ThinkEquity Conference
23 oct. 2024 06h00 HE | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
14 oct. 2024 08h00 HE | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
07 oct. 2024 08h00 HE | Bionomics Ltd
ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics Limited announces intention to re-domicile to the United States
01 oct. 2024 06h30 HE | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 06h30 HE | Bionomics Ltd
ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder
31 juil. 2024 06h30 HE | Bionomics Ltd
Successful End-of-Phase 2 (EoP2) meeting with U.S. Food and Drug Administration (FDA) provides a potential path to New Drug Application (NDA) submission for BNC210 for post-traumatic stress disorder...
bionomics-rgb-1024px.png
Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
29 juil. 2024 16h30 HE | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder
18 juil. 2024 06h30 HE | Bionomics Ltd
Topline results are expected in Q3 2025 ADELAIDE, Australia and CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a biotechnology...
bionomics-rgb-1024px.png
Bionomics Limited Announces Private Placement of up to $70.0 Million
31 mai 2024 08h00 HE | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
20 mai 2024 06h30 HE | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...